Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

In a new study, the researchers have shown that the CRISPR–Cas3 system can induce reliable, extensive deletions of the ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature ...

Waking up this morning to news of the much-deserved Nobel Prize win for Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing" confirms the importance of ...

Technologies at the Advanced Rodent Transgenics Laboratory include genome editing design and implementation and transgenic ...